Rhumbline Advisers Nurix Therapeutics, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 90,918 shares of NRIX stock, worth $1.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

90,918

Previous 88,781 2.41%

Holding current value

$1.8 Million

Previous $1.85 Million 10.21%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$18.93 - $25.69 $40,453 - $54,899	2,137 Added 2.41%	90,918 $2.04 Million
Q2 2024 Aug 01, 2024	BUY	$12.02 - $21.3 $132,340 - $234,513	11,010 Added 14.16%	88,781 $1.85 Million
Q1 2024 May 09, 2024	BUY	$7.77 - $15.66 $20,699 - $41,718	2,664 Added 3.55%	77,771 $1.14 Million
Q4 2023 Feb 08, 2024	BUY	$4.25 - $10.71 $246 - $621	58 Added 0.08%	75,107 $775,000
Q3 2023 Nov 09, 2023	BUY	$7.86 - $10.08 $15,664 - $20,089	1,993 Added 2.73%	75,049 $589,000
Q2 2023 Aug 08, 2023	BUY	$8.7 - $13.28 $2,122 - $3,240	244 Added 0.34%	73,056 $729,000
Q1 2023 May 11, 2023	BUY	$8.56 - $13.26 $17,505 - $27,116	2,045 Added 2.89%	72,812 $647,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $14.59 $6,675 - $9,877	677 Added 0.97%	70,767 $777,000
Q3 2022 Nov 10, 2022	BUY	$12.33 - $19.81 $86,938 - $139,680	7,051 Added 11.19%	70,090 $913,000
Q2 2022 Aug 11, 2022	BUY	$7.88 - $14.82 $232,680 - $437,604	29,528 Added 88.11%	63,039 $799,000
Q1 2022 May 12, 2022	BUY	$12.94 - $29.65 $20,354 - $46,639	1,573 Added 4.93%	33,511 $469,000
Q4 2021 Feb 10, 2022	BUY	$26.43 - $34.5 $22,835 - $29,808	864 Added 2.78%	31,938 $925,000
Q3 2021 Nov 12, 2021	BUY	$22.71 - $36.69 $28,569 - $46,156	1,258 Added 4.22%	31,074 $931,000
Q2 2021 Aug 05, 2021	BUY	$24.21 - $35.89 $135,600 - $201,019	5,601 Added 23.13%	29,816 $791,000
Q1 2021 May 06, 2021	BUY	$26.98 - $50.17 $339,732 - $631,740	12,592 Added 108.34%	24,215 $753,000
Q4 2020 Feb 10, 2021	BUY	$22.85 - $48.44 $48,213 - $102,208	2,110 Added 22.18%	11,623 $382,000
Q3 2020 Nov 12, 2020	BUY	$16.05 - $34.91 $152,683 - $332,098	9,513 New	9,513 $332,000

Others Institutions Holding NRIX

# of Institutions

181

Shares Held

68.1M

Call Options Held

78K

Put Options Held

53.8K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $935M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Nurix Therapeutics, Inc. Transaction History